Beyond depression: Citalopram for obsessive-compulsive disorder

International Clinical Psychopharmacology

Volumn 14, Issue SUPPL. 2, 1999, Pages

  Pato, M T ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

Citalopram; Clomipramine; Fluoxetine; Fluvoxamine; Obsessive compulsive disorder; Paroxetine; Serotonin reuptake inhibitors; Sertraline

Indexed keywords

CITALOPRAM; CLOMIPRAMINE; FLUOXETINE; FLUVOXAMINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

COMPULSION; CONFERENCE PAPER; DEPRESSION; HUMAN; NEUROIMMUNOLOGY; OBSESSION; PRIORITY JOURNAL;

CITALOPRAM; HUMANS; OBSESSIVE-COMPULSIVE DISORDER; SEROTONIN UPTAKE INHIBITORS;

EID: 0032767546     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (45)

1. Bareby JT, Roose SP (1998). SSRI safety in overdose. J Clin Psychiatry 59 (suppl 15):42-48.
2. Baxter LR, Schwartz JM, Mazziotta JC, et al. (1988). Cerebral glucose metabolic rates in nondepressed patients with obsessive-compulsive disorder. Am J Psychiatry 145:1560-1563.
3. Baxter LR, Schwartz JM, Bergman KS, et al. (1992). Caudate glucose metabolic rate changes with both drug and behavioral therapy for obsessive-compulsive disorder. Arch Gen Psychiatry 49:681-689.
4. Bougerol T, Scotto JC, Patris M, Strub N, Lemming O, Petersen HEH (1997). Citalopram and fluoxetine in major depression. Clin Drug Invest August 14:77-89.
5. Breiter HC, Rauch SL, Kwong KK, et al. (1996). Functional magnetic resonance imaging of a symptom provocation in obsessive compulsive disorder. Arch Gen Psychiatry 53:595-606.
6. Clomipramine Collaborative Study Group (1991). Efficacy of clomipramine in OCD: results of a multicenter double-blind trial. Arch Gen Psychiatry 48:730-738.
7. Devane CL (1994). Pharmacokinetics and drug metabolism of newer antidepressant agents. J Clin Psychiatry 55 (suppl 12):38-45.
8. Freeman CPL, Trimble MR, Deakin JFW, et al. (1994). Fluvoxamine versus clomipramine in the treatment of obsessive-compulsive disorder: a multicenter randomized, double-blind, parallel group comparison. J Clin Psychiatry 55:301-305.
9. Goodman WK, Kozak MJ, Liebowitz M, et al. (1996). Treatment of obsessive-compulsive disorder with fluvoxamine: a multicenter, double-blind, placebo-controlled trial. Int Clin Psychopharmacol 11:121-129.
10. Greist JH, Jefferson JW (1998). Pharmacotheapy for obsessive-compulsive disorder. Br J Psychiatry 173 (suppl 35):44-70.
11. Greist JH, Charnard G, Duboff E, et al. (1995a). Double-blind parallel comparison of three dosages of sertraline and placebo in outpatients with obsessive-compulsive disorder. Arch Gen Psychiatry 52:53-60.
12. Griest JH, Jefferson JW, Kobak KA, et al. (1995b). Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder. Arch Gen Psychiatry 52:53-60.
13. Greist JH, Jenike MA, Robinson D, et al. (1995c). Efficacy of fluvoxamine in obsessive-compulsive disorder: results of a multicentre, double-blind placebo-controlled trial. Eur J Clin Res 7:195-204.
14. Hollander E, DeCaria C, Nitescu A, et al. (1992). Serotonergic function in obsessive-compulsive disorder: behavioral and neuroendocrine responses to oral m-chlorophenylpiperazine and fenfluramine in patients and healthy volunteers. Arch Gen Psychiatry 49:21-28.
15. Hyttel J (1994). Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs). Int Clin Psychopharmacol 9 (suppl 1):19-26.
16. Jefferson JQ, Greist JH (1996). The pharmacotherapy of obsessive-compulsive disorder. Psychiatric Annals 26:202-209.
17. Jenike MA, Baer L, Greist JH (1990). Clomipramine versus fluoxetine in obsessive-compulsive disorder: a retrospective comparison of side effects and efficacy. J Clin Psychopharmacol 10:122-124.
18. Karno M, Golding J, Sorenson S, et al. (1988). The epidemiology of obsessive-compulsive disorder in five U.S. communities. Arch Gen Psychiatry 45:1094-1099.
19. Koponen H, Lepola U, Leinonen E, et al. (1997).Citalopram in the treatment of obsessive-compulsive disorder: an open pilot study. Acta Psychiatr Scand 96:343-346.
20. Koran LM, McElroy SL, Davidson JRT, et al. (1996). Fluvoxamine versus clomipramine for obsessive-compulsive disorder: a double-blind comparison. J Clin Psychopharmacol 16:121-129.
21. Lejoyeux M, Ades J (1997). Antidepressant discontinuation: a review of the literature. J Clin Psychiatry 58 (suppl 7):11-16.
22. Lopez-Ibor JJ (1969). Intravenous perfusions of monochlorimipramine: technique and results. In: The Present Status of Psychotropic Drugs. Cerletti A, Bove FJ (editors). Amsterdam: Excerpta Medica Foundation. pp. 519-521.
23. March JS, Frances A, Carpenter D, Kahn DA (1997). Expert Consensus Guidelines series on treatment of obsessive-compulsive disorder. J Clin Psychiatry 58 (suppl 4).
24. Muldoon C (1996). The safety and tolerability of citalopram. Int Clin Psychopharmacol 11:35-40.
25. Mundo E, Bianchi L, Bellodi L (1997). Efficacy of fluvoxamine, paroxetine and citalopram in the treatment of obsessive-compulsive disorder: a single-blind study. J Clin Psychopharmacol 17:267-271.
26. Murphy TK, Goodman WK, Fudge MW, et al. (1997). B lymphocyte antigen D8/17: a peripheral marker for childhood-onset obsessive-compulsive disorder and Tourette's syndrome? Am J Psychiatry 154:402-402.
27. Noble S, Benfield P (1997). Citalopram: a review of its pharmacology, clinical efficacy and tolerabilily in the treatment of depression. CNS Drugs 8:410-431.
28. Pigott TA, Pato MT, Bernstein SE, et al. (1990). Controlled comparison of clomipramine and fluoxetine in the treatment of obsessive-compulsive disorder. Arch Gen Psychiatry 47:926-932.
29. Pigott TA (1996). OCD: where the serotonin selectivity story begins. J Clin Psychiatry 57 (suppl 6):11-20.
30. Rasmussen SA, Baer L, Shera D (1997). Previous SSR1 treatment and efficacy of sertralin for OCD: combined analysis for four multicenter trials. APA Annual Meeting; May 1997; San Diego, CA.
31. Rauch SL, Jenike MA, Alpert NM, et al. (1994). Regional cerebral blood flow measured during symptom provocation in obsessive-compulsive disorder using oxygen 15-labeled carbon dioxide and positron emission tomography. Arch Gen Psychiatry 51:62-70.
32. Robins LN, Helzer JE, Weissman MM, et al. (1984). Lifetime prevalence of specific psychiatric disorders in three sites. Arch Gen Psychiatry 41:958-967.
33. Schwartz JM, Stoessel PW, Baxter LR, et al. (1996). Systematic changes in cerebral glucose metabolic rate after successful behavioral modification treatment of obsessive-compulsive disorder. Arch Gen Psychiatry 53:109-113.
34. Stahl SM (1998). Not so selective serotonin reuptake inhibitors. J Clin Psychiatry 59:343-344.
35. Strauss WL, Layton ME, Hayes CE, Dager SR (1997). 19F magnetic resonance spectroscopy investigation in vivo of acute and steady-state brain fluvoxamine levels in obsessive-compulsive disorder. Am J Psychiatry 154: 516-522.
36. Swedo SE, Rapaport JL, Cheslow DL, et al. (1989). High prevalence of obsessive-compulsive symptoms in patients with Sydenham's chorea. Am J Psychiatry 146:246-249.
37. Swedo SE (1994). Sydenham's Chorea: a model for childhood autoimmune neuropsychiatrie disorders. JAMA 272:1788-1791.
38. Swedo SE, Leonard JL, Mittelman BB, et al. (1997). Identification of children with pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections by a marker associated with rheumatic fever. Am J Psychiatry 154:110-112.
39. Thornsen PH (1997). Child and adolescent obsessive-compulsive disorder treated with citalopram: findings from an open trial of 23 cases. J Child Adolesc Psychopharmacol 7:157-166.
40. Tollefson GD, Birkett M, Koran L, et al. (1994a). Continuation treatment of OCD: double-blind and open-label experience with fluoxetine. J Clin Psychiatry 55 (suppl 10):69-76.
41. Tollefson GD, Rampey AH, Potvin JH, et al. (1994b). A multicenter investigation of fixed dose fluoxetine in the treatment of obsessive-compulsive disorder. Arch Gen Psychiatry 51:559-567.
42. Wheadon D, Bushnell W, Steiner M (1993). A fixed-dose comparison of 20:40, or 60 mg. paroxetine to placebo in the treatment of obsessive-compulsive disorder. ACNP Annual Meeting; December 1993; Honolulu, Hawaii.
43. Yaryura-Tobias JA, Neziroglu F, Bergman L (1976). Clomipramine for obsessive-compulsive neurosis: an organic approach. Curr Ther Res 20:541-547.
44. Zohar J, Mueller E, Insel T, et al. (1987). Serotonergic responsivity in obsessive-compulsive disorder: comparison of patients and healthy controls. Arch Gen Psychiatry 44:946-951.
45. Zohar J, Judge R (1996). Paroxetine versus clomipramine in the treatment of obsessive-compulsive disorder: OCD Paroxetine Study Investigators. Br J Psychiatry 169:468-474.